Crescendo Biologics: Aid for late-stage development
Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme.
Previously, Bland-Ward held senior positions at Cambridge Antibody Technology and PanGenetics and was CSO at Navion, as well as a co-founder of Nascient. He holds a BPharm degree in pharmacy and a PhD in pharmacology, both from King’s College London, and started his career working on pain and migraine research at the Glaxo Institute of Applied Pharmacology and then at GlaxoWellcome.
Orano Med SA
fvm.dk
Office of Congresswoman Ayanna Pressley - https://pressley.house.gov/press-kit/